Trisenox arsenic trioxide: Interim Phase II results; marketed to treat refractory acute promyelocytic leukemia (APL)

CTIC said that Trisenox improved blood cell counts in 3 of 9 patients with

Read the full 140 word article

How to gain access

Continue reading with a
two-week free trial.